Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Verena Wolf

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Cancer Research and Clinical Oncology|June 4, 2021
Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancerWanting Shao, Christina Kuhn, Doris Mayr, et al.
Journal of Cancer Research and Clinical Oncology|July 16, 2021
Correction to: Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancerWanting Shao, Christina Kuhn, Doris Mayr, et al.
Journal of Translational Medicine|February 23, 2020
Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancersWanting Shao, Christina Kuhn, Doris Mayr, et al.
Plos Genetics|July 5, 2012
In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferasesJulia Arand, David Spieler, Tommy Karius, et al.
Cell Reports Methods|April 27, 2022
A comprehensive approach for genome-wide efficiency profiling of DNA modifying enzymesCharalampos Kyriakopoulos, Karl Nordström, Paula Linh Kramer, et al.
BMC Cancer|April 18, 2018
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancerAnna Semmlinger, Viktoria von Schoenfeldt, Verena Wolf, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Cancer Research and Clinical Oncology|June 4, 2021
Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancerWanting Shao, Christina Kuhn, Doris Mayr, et al.
Journal of Cancer Research and Clinical Oncology|July 16, 2021
Correction to: Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancerWanting Shao, Christina Kuhn, Doris Mayr, et al.
Journal of Translational Medicine|February 23, 2020
Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancersWanting Shao, Christina Kuhn, Doris Mayr, et al.
Plos Genetics|July 5, 2012
In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferasesJulia Arand, David Spieler, Tommy Karius, et al.
Cell Reports Methods|April 27, 2022
A comprehensive approach for genome-wide efficiency profiling of DNA modifying enzymesCharalampos Kyriakopoulos, Karl Nordström, Paula Linh Kramer, et al.
BMC Cancer|April 18, 2018
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancerAnna Semmlinger, Viktoria von Schoenfeldt, Verena Wolf, et al.
Pageof 3